O	0	6	Effect
O	7	9	of
B-intervention	10	16	Longer
I-intervention	16	17	-
I-intervention	17	25	Interval
O	26	28	vs
B-control	29	37	Standard
I-control	38	44	Dosing
I-control	45	47	of
I-control	48	58	Zoledronic
I-control	59	63	Acid
O	64	66	on
O	67	75	Skeletal
O	76	82	Events
O	83	85	in
O	86	94	Patients
O	95	99	With
B-condition	100	104	Bone
I-condition	105	115	Metastases
O	115	116	:
O	117	118	A
O	119	129	Randomized
O	130	138	Clinical
O	139	144	Trial
O	144	145	.

O	146	156	Zoledronic
O	157	161	acid
O	161	162	,
O	163	164	a
O	165	170	third
O	170	171	-
O	171	181	generation
O	182	201	aminobisphosphonate
O	201	202	,
O	203	210	reduces
O	211	214	the
O	215	224	incidence
O	225	227	of
O	228	236	skeletal
O	236	237	-
O	237	244	related
O	245	251	events
O	252	255	and
O	256	260	pain
O	261	263	in
O	264	272	patients
O	273	277	with
O	278	282	bone
O	283	293	metastases
O	293	294	.

O	295	298	The
O	299	306	optimal
O	307	313	dosing
O	314	322	interval
O	323	326	for
O	327	337	zoledronic
O	338	342	acid
O	343	345	is
O	346	355	uncertain
O	355	356	.

O	357	359	To
O	360	369	determine
O	370	377	whether
O	378	388	zoledronic
O	389	393	acid
O	394	406	administered
O	407	412	every
O	413	415	12
O	416	421	weeks
O	422	424	is
O	425	436	noninferior
O	437	439	to
O	440	450	zoledronic
O	451	455	acid
O	456	468	administered
O	469	474	every
O	475	476	4
O	477	482	weeks
O	482	483	.

O	484	494	Randomized
O	494	495	,
O	496	500	open
O	500	501	-
O	501	506	label
O	507	515	clinical
O	516	521	trial
O	522	531	conducted
O	532	534	at
O	535	538	269
O	539	547	academic
O	548	551	and
O	552	561	community
O	562	567	sites
O	568	570	in
O	571	574	the
B-location	575	581	United
I-location	582	588	States
O	588	589	.

O	590	598	Patients
O	599	600	(
O	600	601	n
O	602	603	=
B-total-participants	604	608	1822
O	608	609	)
B-eligibility	610	614	with
I-eligibility	615	625	metastatic
I-eligibility	626	632	breast
I-eligibility	633	639	cancer
I-eligibility	639	640	,
I-eligibility	641	651	metastatic
I-eligibility	652	660	prostate
I-eligibility	661	667	cancer
I-eligibility	667	668	,
I-eligibility	669	671	or
I-eligibility	672	680	multiple
I-eligibility	681	688	myeloma
I-eligibility	689	692	who
I-eligibility	693	696	had
I-eligibility	697	699	at
I-eligibility	700	705	least
I-eligibility	706	707	1
I-eligibility	708	712	site
I-eligibility	713	715	of
I-eligibility	716	720	bone
I-eligibility	721	732	involvement
O	733	737	were
O	738	746	enrolled
O	747	754	between
O	755	758	May
O	759	763	2009
O	764	767	and
O	768	773	April
O	774	778	2012
O	778	779	;
O	780	786	follow
O	786	787	-
O	787	789	up
O	790	799	concluded
O	800	802	in
O	803	808	April
O	809	813	2014
O	813	814	.

O	815	823	Patients
O	824	828	were
O	829	839	randomized
O	840	842	to
O	843	850	receive
O	851	861	zoledronic
O	862	866	acid
O	867	879	administered
O	880	893	intravenously
O	894	899	every
O	900	901	4
O	902	907	weeks
O	908	909	(
O	909	910	n
O	911	912	=
B-control-participants	913	916	911
O	916	917	)
O	918	920	vs
O	921	926	every
O	927	929	12
O	930	935	weeks
O	936	937	(
O	937	938	n
O	939	940	=
B-intervention-participants	941	944	911
O	944	945	)
O	946	949	for
O	950	951	2
O	952	957	years
O	957	958	.

O	959	962	The
O	963	970	primary
O	971	974	end
O	975	980	point
O	981	984	was
O	985	988	the
B-outcome-Measure	989	999	proportion
I-outcome-Measure	1000	1002	of
I-outcome-Measure	1003	1011	patients
I-outcome-Measure	1012	1018	having
I-outcome-Measure	1019	1021	at
I-outcome-Measure	1022	1027	least
I-outcome-Measure	1028	1029	1
I-outcome-Measure	1030	1038	skeletal
I-outcome-Measure	1038	1039	-
I-outcome-Measure	1039	1046	related
I-outcome-Measure	1047	1052	event
O	1053	1054	(
O	1054	1061	defined
O	1062	1064	as
O	1065	1073	clinical
O	1074	1082	fracture
O	1082	1083	,
O	1084	1090	spinal
O	1091	1095	cord
O	1096	1107	compression
O	1107	1108	,
O	1109	1118	radiation
O	1119	1121	to
O	1122	1126	bone
O	1126	1127	,
O	1128	1130	or
O	1131	1138	surgery
O	1139	1148	involving
O	1149	1153	bone
O	1153	1154	)
O	1155	1161	within
O	1162	1163	2
O	1164	1169	years
O	1170	1175	after
O	1176	1189	randomization
O	1190	1193	and
O	1194	1195	a
O	1196	1203	between
O	1203	1204	-
O	1204	1209	group
O	1210	1218	absolute
O	1219	1229	difference
O	1230	1232	of
O	1233	1234	7
O	1234	1235	%
O	1236	1238	as
O	1239	1242	the
O	1243	1257	noninferiority
O	1258	1264	margin
O	1264	1265	.

O	1266	1275	Secondary
O	1276	1279	end
O	1280	1286	points
O	1287	1295	included
O	1296	1299	the
B-outcome-Measure	1300	1310	proportion
I-outcome-Measure	1311	1313	of
I-outcome-Measure	1314	1322	patients
I-outcome-Measure	1323	1327	with
I-outcome-Measure	1328	1330	at
I-outcome-Measure	1331	1336	least
I-outcome-Measure	1337	1338	1
I-outcome-Measure	1339	1347	skeletal
I-outcome-Measure	1347	1348	-
I-outcome-Measure	1348	1355	related
I-outcome-Measure	1356	1361	event
I-outcome-Measure	1362	1364	by
I-outcome-Measure	1365	1372	disease
I-outcome-Measure	1373	1377	type
O	1377	1378	,
B-outcome-Measure	1379	1383	pain
O	1384	1386	as
O	1387	1395	assessed
O	1396	1398	by
O	1399	1402	the
O	1403	1408	Brief
O	1409	1413	Pain
O	1414	1423	Inventory
O	1424	1425	(
O	1425	1430	range
O	1430	1431	,
O	1432	1433	0
O	1433	1434	-
O	1434	1436	10
O	1436	1437	;
O	1438	1444	higher
O	1445	1451	scores
O	1452	1460	indicate
O	1461	1466	worse
O	1467	1471	pain
O	1471	1472	)
O	1472	1473	,
B-outcome-Measure	1474	1481	Eastern
I-outcome-Measure	1482	1493	Cooperative
I-outcome-Measure	1494	1502	Oncology
I-outcome-Measure	1503	1508	Group
I-outcome-Measure	1509	1520	performance
I-outcome-Measure	1521	1527	status
O	1528	1529	(
O	1529	1534	range
O	1534	1535	,
O	1536	1537	0
O	1537	1538	-
O	1538	1539	4
O	1539	1540	;
O	1541	1547	higher
O	1548	1554	scores
O	1555	1563	indicate
O	1564	1569	worse
O	1570	1580	disability
O	1580	1581	)
O	1581	1582	,
B-outcome-Measure	1583	1592	incidence
I-outcome-Measure	1593	1595	of
I-outcome-Measure	1596	1609	osteonecrosis
I-outcome-Measure	1610	1612	of
I-outcome-Measure	1613	1616	the
I-outcome-Measure	1617	1620	jaw
O	1620	1621	,
B-outcome-Measure	1622	1628	kidney
I-outcome-Measure	1629	1640	dysfunction
O	1640	1641	,
B-outcome-Measure	1642	1650	skeletal
I-outcome-Measure	1651	1660	morbidity
I-outcome-Measure	1661	1665	rate
O	1666	1667	(
O	1667	1671	mean
O	1672	1678	number
O	1679	1681	of
O	1682	1690	skeletal
O	1690	1691	-
O	1691	1698	related
O	1699	1705	events
O	1706	1709	per
O	1710	1714	year
O	1714	1715	)
O	1715	1716	,
O	1717	1720	and
O	1720	1721	,
O	1722	1724	in
O	1725	1726	a
O	1727	1733	subset
O	1734	1736	of
O	1737	1740	553
O	1741	1749	patients
O	1749	1750	,
B-outcome-Measure	1751	1762	suppression
I-outcome-Measure	1763	1765	of
I-outcome-Measure	1766	1770	bone
I-outcome-Measure	1771	1779	turnover
O	1780	1781	(
O	1781	1789	assessed
O	1790	1792	by
O	1793	1794	C
O	1794	1795	-
O	1795	1803	terminal
O	1804	1815	telopeptide
O	1816	1822	levels
O	1822	1823	)
O	1823	1824	.

O	1825	1830	Among
B-total-participants	1831	1835	1822
O	1836	1844	patients
O	1845	1848	who
O	1849	1853	were
O	1854	1864	randomized
O	1865	1866	(
O	1866	1872	median
O	1873	1876	age
O	1876	1877	,
B-age	1878	1880	65
I-age	1881	1886	years
O	1886	1887	;
O	1888	1891	980
O	1892	1893	[
O	1893	1895	53
O	1895	1896	.
O	1896	1897	8
O	1897	1898	%
O	1898	1899	]
O	1900	1905	women
O	1905	1906	;
O	1907	1910	855
O	1911	1915	with
O	1916	1922	breast
O	1923	1929	cancer
O	1929	1930	,
O	1931	1934	689
O	1935	1939	with
O	1940	1948	prostate
O	1949	1955	cancer
O	1955	1956	,
O	1957	1960	and
O	1961	1964	278
O	1965	1969	with
O	1970	1978	multiple
O	1979	1986	myeloma
O	1986	1987	)
O	1987	1988	,
O	1989	1992	795
O	1993	2002	completed
O	2003	2006	the
O	2007	2012	study
O	2013	2015	at
O	2016	2017	2
O	2018	2023	years
O	2023	2024	.

O	2025	2026	A
O	2027	2032	total
O	2033	2035	of
B-control-participants	2036	2039	260
O	2040	2048	patients
O	2049	2050	(
B-cv-bin-percent	2050	2052	29
I-cv-bin-percent	2052	2053	.
I-cv-bin-percent	2053	2054	5
I-cv-bin-percent	2054	2055	%
O	2055	2056	)
O	2057	2059	in
O	2060	2063	the
O	2064	2074	zoledronic
O	2075	2079	acid
O	2080	2085	every
O	2086	2087	4
O	2087	2088	-
O	2088	2092	week
O	2093	2099	dosing
O	2100	2105	group
O	2106	2109	and
B-intervention-participants	2110	2113	253
O	2114	2122	patients
O	2123	2124	(
B-iv-bin-percent	2124	2126	28
I-iv-bin-percent	2126	2127	.
I-iv-bin-percent	2127	2128	6
I-iv-bin-percent	2128	2129	%
O	2129	2130	)
O	2131	2133	in
O	2134	2137	the
O	2138	2143	every
O	2144	2146	12
O	2146	2147	-
O	2147	2151	week
O	2152	2158	dosing
O	2159	2164	group
O	2165	2176	experienced
O	2177	2179	at
O	2180	2185	least
O	2186	2187	1
B-outcome	2188	2196	skeletal
I-outcome	2196	2197	-
I-outcome	2197	2204	related
I-outcome	2205	2210	event
O	2211	2217	within
O	2218	2219	2
O	2220	2225	years
O	2226	2228	of
O	2229	2242	randomization
O	2243	2244	(
O	2244	2248	risk
O	2249	2259	difference
O	2260	2262	of
O	2263	2264	-
O	2264	2265	0
O	2265	2266	.
O	2266	2267	3
O	2267	2268	%
O	2269	2270	[
O	2270	2271	1
O	2271	2272	-
O	2272	2277	sided
O	2278	2280	95
O	2280	2281	%
O	2282	2284	CI
O	2284	2285	,
O	2286	2287	-
O	2287	2288	4
O	2288	2289	%
O	2290	2292	to
O	2293	2294	âˆž
O	2294	2295	]
O	2295	2296	;
O	2297	2298	P
O	2299	2300	<
O	2301	2302	.
O	2302	2305	001
O	2306	2309	for
O	2310	2324	noninferiority
O	2324	2325	)
O	2325	2326	.

O	2327	2330	The
B-outcome	2331	2342	proportions
I-outcome	2343	2345	of
I-outcome	2346	2354	skeletal
I-outcome	2354	2355	-
I-outcome	2355	2362	related
I-outcome	2363	2369	events
O	2370	2373	did
O	2374	2377	not
O	2378	2384	differ
O	2385	2398	significantly
O	2399	2406	between
O	2407	2410	the
O	2411	2416	every
O	2417	2418	4
O	2418	2419	-
O	2419	2423	week
O	2424	2430	dosing
O	2431	2436	group
O	2437	2439	vs
O	2440	2443	the
O	2444	2449	every
O	2450	2452	12
O	2452	2453	-
O	2453	2457	week
O	2458	2464	dosing
O	2465	2470	group
O	2471	2474	for
O	2475	2483	patients
O	2484	2488	with
O	2489	2495	breast
O	2496	2502	cancer
O	2502	2503	,
O	2504	2512	prostate
O	2513	2519	cancer
O	2519	2520	,
O	2521	2523	or
O	2524	2532	multiple
O	2533	2540	myeloma
O	2540	2541	.

B-outcome	2542	2546	Pain
I-outcome	2547	2553	scores
O	2553	2554	,
B-outcome	2555	2566	performance
I-outcome	2567	2573	status
I-outcome	2574	2580	scores
O	2580	2581	,
B-outcome	2582	2591	incidence
I-outcome	2592	2594	of
I-outcome	2595	2598	jaw
I-outcome	2599	2612	osteonecrosis
O	2612	2613	,
O	2614	2617	and
B-outcome	2618	2624	kidney
I-outcome	2625	2636	dysfunction
O	2637	2640	did
O	2641	2644	not
O	2645	2651	differ
O	2652	2665	significantly
O	2666	2673	between
O	2674	2677	the
O	2678	2687	treatment
O	2688	2694	groups
O	2694	2695	.

B-outcome	2696	2704	Skeletal
I-outcome	2705	2714	morbidity
I-outcome	2715	2720	rates
O	2721	2725	were
O	2726	2737	numerically
O	2738	2747	identical
O	2748	2750	in
O	2751	2755	both
O	2756	2762	groups
O	2762	2763	,
O	2764	2767	but
B-outcome	2768	2772	bone
I-outcome	2773	2781	turnover
O	2782	2785	was
O	2786	2793	greater
O	2794	2795	(
O	2795	2796	C
O	2796	2797	-
O	2797	2805	terminal
O	2806	2817	telopeptide
O	2818	2824	levels
O	2825	2829	were
O	2830	2836	higher
O	2836	2837	)
O	2838	2843	among
O	2844	2852	patients
O	2853	2856	who
O	2857	2865	received
O	2866	2876	zoledronic
O	2877	2881	acid
O	2882	2887	every
O	2888	2890	12
O	2891	2896	weeks
O	2896	2897	.

O	2898	2903	Among
O	2904	2912	patients
O	2913	2917	with
O	2918	2922	bone
O	2923	2933	metastases
O	2934	2937	due
O	2938	2940	to
O	2941	2947	breast
O	2948	2954	cancer
O	2954	2955	,
O	2956	2964	prostate
O	2965	2971	cancer
O	2971	2972	,
O	2973	2975	or
O	2976	2984	multiple
O	2985	2992	myeloma
O	2992	2993	,
O	2994	2997	the
O	2998	3001	use
O	3002	3004	of
O	3005	3015	zoledronic
O	3016	3020	acid
O	3021	3026	every
O	3027	3029	12
O	3030	3035	weeks
O	3036	3044	compared
O	3045	3049	with
O	3050	3053	the
O	3054	3062	standard
O	3063	3069	dosing
O	3070	3078	interval
O	3079	3081	of
O	3082	3087	every
O	3088	3089	4
O	3090	3095	weeks
O	3096	3099	did
O	3100	3103	not
O	3104	3110	result
O	3111	3113	in
O	3114	3116	an
O	3117	3126	increased
B-outcome	3127	3131	risk
I-outcome	3132	3134	of
I-outcome	3135	3143	skeletal
I-outcome	3144	3150	events
O	3151	3155	over
O	3156	3157	2
O	3158	3163	years
O	3163	3164	.

O	3165	3169	This
O	3170	3176	longer
O	3177	3185	interval
O	3186	3189	may
O	3190	3192	be
O	3193	3195	an
O	3196	3206	acceptable
O	3207	3216	treatment
O	3217	3223	option
O	3223	3224	.
O	3225	3239	clinicaltrials
O	3239	3240	.
O	3240	3243	gov
O	3244	3254	Identifier
O	3254	3255	:
O	3256	3267	NCT00869206
O	3267	3268	.
